Celcuity

Celcuity Equity Growth

The Year-over-Year Equity Growth of Celcuity (CELC) as of Nov 11, 2026 is -13.03 %. In the previous year, Year-over-Year Equity Growth was -17.28 % — a change of -24.59% (higher).

Equity Growth

-13.03 %

YoY

-24.59%

Last updated:

Year-over-Year Equity Growth of Celcuity is 2025 -13.03 % . Year-over-Year Equity Growth of Celcuity was 2024 -17.28 % . It decreases by -24.59% higher compared to the previous year.

The Celcuity Equity Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Growth
Date
Equity Growth
Jan 1, 2018
-19.25 USD
Jan 1, 2019
-23.87 USD
Jan 1, 2020
-39.36 USD
Jan 1, 2021
487.16 USD
Jan 1, 2022
94.69 USD
Jan 1, 2023
4.48 USD
Jan 1, 2024
-17.28 USD
Jan 1, 2025
-13.03 USD
The Celcuity Equity Growth history
YEAREquity GrowthYoY
-13.03 %-24.59%
-17.28 %-485.37%
4.48 %-95.26%
94.69 %-80.56%
487.16 %-1,337.73%
-39.36 %+64.86%
-23.87 %+24.04%
-19.25 %-104.19%
459.40 %+3,771.91%
11.86 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Celcuity Stock analysis

What does Celcuity do? Celcuity Inc is a biotechnology company founded by Brian Sullivan in 2012. The company is headquartered in Minneapolis, USA. The business model of Celcuity is based on researching and developing new diagnostic and treatment methods for various types of cancer. The company utilizes a proprietary technology platform called CELx, which enables the analysis of cancer cell signaling pathways and the development of individualized treatment strategies. Celcuity specializes in the development of diagnostics and personalized therapies based on individual cancer cell signaling pathways. The company operates in two divisions: 1. Diagnostics division: Celcuity's diagnostics division focuses on identifying new cancer markers and biomarkers for early detection of cancer and the development of individualized treatment strategies. 2. Therapy division: Celcuity's therapy division specializes in the development of personalized therapies based on individual cancer cell signaling pathways. Celcuity currently offers two products based on the CELx technology platform: 1. CELx HUB: CELx HUB is a cloud-based software that allows doctors and researchers to analyze cancer samples and develop individualized treatment strategies. 2. CELx TIL: CELx TIL is a diagnostic tool that measures the presence of tumor cells in the immune system of cancer patients. In summary, Celcuity Inc is a leader in the field of personalized cancer therapy based on individual cancer cell signaling pathways. The company has found a niche in this growing market and has a unique technology platform that allows it to serve its customers effectively. With its products and services, Celcuity is helping to revolutionize cancer treatment and improve the quality of life for cancer patients worldwide. Celcuity is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Celcuity stock

Year-over-Year Equity Growth of Celcuity is -13.03 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Equity Growth Celcuity since 2006 – with annual values, charts, and detailed analysis.

Equity growth measures the percentage change in shareholders' equity. It reflects retained earnings, share issuances, and comprehensive income effects.

To evaluate Year-over-Year Equity Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Equity Growth.

Year-over-Year Equity Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Equity Growth's Celcuity historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Celcuity

All Key Metrics — Celcuity